PMI · Picard Medical, Inc.
$11.21
-4.24 (-27.44%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this filing are issued.”View the 10-Q filed Aug 19, 2026
Market Cap
$36.13M
Shares
2.34M
Volume · Oct 20
1M
Avg daily vol (56 sessions)
1.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.48
Open$15.20
Day$10.14–17.47
52W close$3.03–660.00
Avg vol 30d474K
Short int38K · 1.6% float · 1.0d
Short vol48%
Last earningsMar 25, 2026
DataAug 2025–Oct 2026
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$6.29M
Trailing 12 months
Net income (TTM)
−$27.99M
Trailing 12 months
Revenue growth YoY
+38.6%
Year over year
Operating margin
-248.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+356.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.6%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−69%
below
Price vs 50-day avg
+61%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+142%
trailing
6-month return
−77%
trailing
YTD return
−88%
this year
Relative strength
−85%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $34 — 200d above 50d
Institutional flow
Distributing
6 of 40 funds reported for Sep 30 · net -1.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.61% of float · ▼ -83.8% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
40 holders — near 1-yr high, broad support
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+13%
Y/Y
Gross margin
-4%
contracting
EPS growth
+75%
Y/Y
Quant / Vol
risk profile
Volatility
233%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
27.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−69%
Bearish
Price vs 50-day avg
+61%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $34 — 200d above 50d
Institutional flow
Distributing
6 of 40 funds reported for Sep 30 · net -1.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.61% of float · ▼ -83.8% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
40 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $10 · 1%
Range high $660
vs 200-day avg -69%
vs 50-day avg +61%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMI
this stock
Picard Medical, Inc.
|
$36.13M | — | +12.5% | — | 1.6% |
|
ABT
Abbott Laboratories
|
$179.20B | -18.2% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$118.67B | -1.5% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -13.4% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.02B | -52.2% | +12.5% | 18.4 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 13, 2026
- This year
- 48
Picard Medical, Inc.’s Board approved an amendment effective October 7, 2026, reducing the stockholder-meeting quorum from a majority to thirty-three and one-third percent (33 1/3%) of voting power.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMI | -31.6% | +142.0% | -76.7% | +149.5% | -88.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -30.5% | +142.6% | -84.8% | +148.7% | -100.8% |